Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Terminated 2Completed 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Dermatologic 1

Conditions

Small Cell Lung Carcinoma 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1

Interventions

Cyclophosphamide 910Carboplatin 788pembrolizumab 747Paclitaxel 744Bevacizumab 716Cisplatin 709Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 339Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × 7-hydroxystaurosporine × Clear all
NCT00098956 2018-07-23

7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
19 enrolled 9 charts
Thoracic

Small Cell Lung Carcinoma

NCT00082017 2017-05-15

UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
20 enrolled 13 charts
Lymphoid

Lymphoma, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT00072189 2015-03-02

A Phase II Study of UCN-01 in Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Terminated
17 enrolled 6 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡